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Editorials 
Chemical castration for sex offenders 
Doctors should avoid becoming agents of social control  
In November 2009, in response to several high profile sex offences committed against 
children, Polish President Lech Kaczynski signed a law allowing for the compulsory 
treatment of some sex offenders with antiandrogenic drugs, commonly referred to as 
chemical castration. Following a sexual killing carried out by a repeat sex offender in 
France, the French National Assembly is considering legislation that would make 
chemical castration mandatory for some sex offenders. Laws in several American 
states allow compulsory medical treatment of offenders who have committed serious 
sex offences. Chemical, as well as physical, castration of sex offenders takes place in 
psychiatric hospitals in the Czech Republic under the legal framework of "protective 
treatment." Meanwhile, in England the Department of Health is supporting an 
initiative to facilitate the prescription of drugs on a voluntary basis for sex offenders 
in the criminal justice system.1  
Demand for the prescription of antiandrogens or physical castration for sex offenders 
is a common reaction by lawmakers and politicians when a high profile sexual crime 
is committed. Although castration is ostensibly for public protection, it also carries 
with it a sense of symbolic retribution. Whether medical or surgical, the procedure 
requires the participation of doctors, and this gives rise to questions regarding the 
basis of medical involvement. Some people argue that not only does medical input in 
these cases straddle the border between treatment and punishment,2 but that it also 
shifts the doctor’s focus from the best interests of the patient to one of public safety.  
Antiandrogenic drugs and physical castration undoubtedly reduce sexual interest 
(libido) and sexual performance,3 and they reduce sexual reoffending. Physical 
castration of sex offenders was carried out in several European countries in the first 
part of the 20th century, and although morally dubious and not always targeted at high 
risk cases (many of those castrated were homosexual, mentally ill, or learning 
disabled), recidivism rates of less than 5% over long follow-up periods are invariably 
reported, compared with expected rates of 50% or more.4  
Studies of the use of antiandrogenic drugs report similar efficacy,5 6 7 and a large 
meta-analysis of treatment in sex offenders found that "organic" interventions 
(surgical castration and hormones) reduce recidivism much more than any other 
treatment approach (although the authors found that nowadays drugs are usually used 
alongside psychological treatment).8 Double blind placebo controlled studies of 
antiandrogens are virtually absent because of the practical difficulties of carrying them 
out (among other things, it is not easy to convince an ethics committee of the wisdom 
of giving placebo to dangerous offenders), but the evidence supports the efficacy of 
these treatments.  
It is not surprising that antiandrogens have such a big effect on the risk of sexual 
offences. Regardless of the strong psychological factors that contribute to sexual 
offending, at its root lies the pressure exerted by sexual drive and sexual arousal, 
mediated by biological mechanisms dependent on testosterone. The main drugs used 
are cyproterone acetate (in the United Kingdom, Europe, and Canada); 
medroxyprogesterone (in the United States); and increasingly the more expensive but 
possibly more potent gonadotrophin releasing hormone agonists such as leuprolide, 
goserelin, and tryptorelin.9 10 Although these drugs act in different ways, they all 
reduce serum testosterone concentrations in men to prepubertal values. Castration, 
however—whether chemical or physical—is associated with serious side effects, 
including osteoporosis, cardiovascular disease, metabolic abnormalities, and 
gynaecomastia. Physical castration is mutilating and irreversible, and it carries the 
potential for serious psychological disturbance, although some offenders request it 
nonetheless.11  
Given the risk to the individual’s health, is there a clear medical rather than social 
reason for prescribing powerful drugs, let alone carrying out such a drastic surgical 
procedure? Part of the problem lies in the poor diagnostic conceptualisation of the 
sexual deviations, with DSM-IV-TR (Diagnostic and Statistical Manual of Mental 
Disorders, fourth edition, text revision) and ICD-10 (International Classification of 
Diseases, 10th revision) definitions dominated by notions of the unconventional 
nature of the drive, rather than its psychological or physical characteristics. When the 
intensity or ability to control sexual arousal is the presenting feature—whether it 
manifests as frequent rumination and fantasy or strong and recurrent urges—then 
treatment directed towards the biological drive makes sense. Treatment protocols can 
then be based on the medical indication (remembering that drugs other than the 
antiandrogens, such as selective serotonin reuptake inhibitors, can also be effective, 
particularly when sexual rumination is the presenting problem12) rather than on risk.  
When drugs work the clinical effect is often dramatic, with offenders reporting great 
benefit from no longer being preoccupied by sexual thoughts or dominated by sexual 
drive. These drugs can also allow offenders to participate in psychological treatment 
programmes where previously they may have been too distracted to take part. Given 
the transparency of benefits and risks, there is no obvious reason why an offender 
should not be able to make an informed choice about drugs. Some argue that freedom 
of choice is lost in instances where long term detention is the only alternative to 
drugs,2 but it is not clear why this should not be part of the person’s calculation. 
Indeed, preventing this choice may condemn men to years of further imprisonment.  
Overall, it probably makes most sense for medical treatment to be viewed as part of a 
wider package of care and supervision, dependent on the individual’s consent but with 
no decisions wholly dependent on compliance. In this context, the doctor does not 
assume responsibility for public safety but contributes to it by helping the offender to 
tackle those factors that make him more likely to reoffend.6 Physical castration as part 
of a rehabilitative strategy may even have a place, although the observations of the 
Council of Europe’s committee for the prevention of torture 
(www.cpt.coe.int/documents/cze/2009-08-inf-eng.pdf) should not be overlooked 
given the significant risk of human rights abuses, with individuals acquiescing rather 
than consenting in the belief that it is the only way to avoid indefinite confinement.  
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